Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Esnouf

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Virology|August 16, 2001
Mutations at amino acid positions 63, 189, and 396 of human immunodeficiency virus type 1 reverse transcriptase (RT) partially restore the DNA polymerase activity of a Trp229Tyr mutant RTH Pelemans, R Esnouf, K L Min, et al.
Journal of Medicinal Chemistry|March 15, 2000
Design, synthesis, and enzymatic evaluation of multisubstrate analogue inhibitors of Escherichia coli thymidine phosphorylaseA Esteban-Gamboa, J Balzarini, R Esnouf, et al.
Molecular Pharmacology|July 1, 1999
Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compoundsS Liekens, D Leali, J Neyts, et al.
Nature Structural Biology|April 1, 1995
High resolution structures of HIV-1 RT from four RT-inhibitor complexesJ Ren, R Esnouf, E Garman, et al.
FEBS Letters|November 20, 1998
7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylaseJ Balzarini, A E Gamboa, R Esnouf, et al.
FEBS Letters|October 24, 2000
Kinetic analysis of novel multisubstrate analogue inhibitors of thymidine phosphorylaseJ Balzarini, B Degrève, A Esteban-Gamboa, et al.
Journal of Virology|October 29, 1997
Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1H Pelemans, R Esnouf, A Dunkler, et al.
AIDS (London, England)|April 24, 2001
Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotypeK Van Laethem, M Witvrouw, C Pannecouque, et al.
Antimicrobial Agents and Chemotherapy|March 28, 1998
1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activityM Witvrouw, M E Arranz, C Pannecouque, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Virology|August 16, 2001
Mutations at amino acid positions 63, 189, and 396 of human immunodeficiency virus type 1 reverse transcriptase (RT) partially restore the DNA polymerase activity of a Trp229Tyr mutant RTH Pelemans, R Esnouf, K L Min, et al.
Journal of Medicinal Chemistry|March 15, 2000
Design, synthesis, and enzymatic evaluation of multisubstrate analogue inhibitors of Escherichia coli thymidine phosphorylaseA Esteban-Gamboa, J Balzarini, R Esnouf, et al.
Molecular Pharmacology|July 1, 1999
Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compoundsS Liekens, D Leali, J Neyts, et al.
Nature Structural Biology|April 1, 1995
High resolution structures of HIV-1 RT from four RT-inhibitor complexesJ Ren, R Esnouf, E Garman, et al.
FEBS Letters|November 20, 1998
7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylaseJ Balzarini, A E Gamboa, R Esnouf, et al.
FEBS Letters|October 24, 2000
Kinetic analysis of novel multisubstrate analogue inhibitors of thymidine phosphorylaseJ Balzarini, B Degrève, A Esteban-Gamboa, et al.
Journal of Virology|October 29, 1997
Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1H Pelemans, R Esnouf, A Dunkler, et al.
AIDS (London, England)|April 24, 2001
Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotypeK Van Laethem, M Witvrouw, C Pannecouque, et al.
Antimicrobial Agents and Chemotherapy|March 28, 1998
1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activityM Witvrouw, M E Arranz, C Pannecouque, et al.
Pageof 2